Table 4.

Patient participation



Treatment group


PCT, n (%) n = 318
Control, n (%) n = 327
P
Completed transfusion period   280 (88)   294 (90)   .53  
Reason for not completing transfusion period     
   Patient decided to withdraw   8 (2.5)   4 (1.2)   .26  
   Physician withdrew patient   10 (3.1)   4 (1.2)   .11  
   Adverse event(s)   0 (0)   0 (0)   —  
   Lost to follow-up   1 (< 1)   1 (< 1)   —  
   Death   10 (3.1)   15 (4.6)   .42  
   Other   9 (2.8)   9 (2.8)   —  
   Total   38 (11.9)   33 (10.1)   .44  
Mean days of platelet support   11.8   10.6   .08  
Achieved and maintained platelet independence prior to day 28   210 (66)   230 (70)   .27  
Completed surveillance period
 
248 (78)
 
273 (84)
 
.09
 


Treatment group


PCT, n (%) n = 318
Control, n (%) n = 327
P
Completed transfusion period   280 (88)   294 (90)   .53  
Reason for not completing transfusion period     
   Patient decided to withdraw   8 (2.5)   4 (1.2)   .26  
   Physician withdrew patient   10 (3.1)   4 (1.2)   .11  
   Adverse event(s)   0 (0)   0 (0)   —  
   Lost to follow-up   1 (< 1)   1 (< 1)   —  
   Death   10 (3.1)   15 (4.6)   .42  
   Other   9 (2.8)   9 (2.8)   —  
   Total   38 (11.9)   33 (10.1)   .44  
Mean days of platelet support   11.8   10.6   .08  
Achieved and maintained platelet independence prior to day 28   210 (66)   230 (70)   .27  
Completed surveillance period
 
248 (78)
 
273 (84)
 
.09
 

— indicates not applicable.

or Create an Account

Close Modal
Close Modal